- Home
- FINW vs CERS Comparison
FINW vs CERS Comparison
Compare FINW & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- CERS
- Stock Information
- Founded
- FINW 1999
- CERS 1991
- Country
- FINW United States
- CERS United States
- Employees
- FINW N/A
- CERS N/A
- Industry
- FINW Commercial Banks
- CERS EDP Services
- Sector
- FINW Finance
- CERS Technology
- Exchange
- FINW Nasdaq
- CERS Nasdaq
- Market Cap
- FINW 242.1M
- CERS 276.0M
- IPO Year
- FINW 2021
- CERS 1997
- Fundamental
- Price
- FINW $19.08
- CERS $1.72
- Analyst Decision
- FINW Buy
- CERS Buy
- Analyst Count
- FINW 3
- CERS 1
- Target Price
- FINW $21.67
- CERS $4.00
- AVG Volume (30 Days)
- FINW 13.2K
- CERS 1.2M
- Earning Date
- FINW 10-29-2025
- CERS 11-06-2025
- Dividend Yield
- FINW N/A
- CERS N/A
- EPS Growth
- FINW N/A
- CERS N/A
- EPS
- FINW 1.05
- CERS N/A
- Revenue
- FINW $80,199,000.00
- CERS $199,191,000.00
- Revenue This Year
- FINW $72.14
- CERS $19.07
- Revenue Next Year
- FINW $47.30
- CERS $12.03
- P/E Ratio
- FINW $18.24
- CERS N/A
- Revenue Growth
- FINW 14.76
- CERS 13.03
- 52 Week Low
- FINW $13.49
- CERS $1.12
- 52 Week High
- FINW $22.49
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- FINW 54.44
- CERS 62.45
- Support Level
- FINW $18.51
- CERS $1.38
- Resistance Level
- FINW $19.80
- CERS $1.54
- Average True Range (ATR)
- FINW 0.67
- CERS 0.09
- MACD
- FINW 0.16
- CERS 0.00
- Stochastic Oscillator
- FINW 70.29
- CERS 98.55
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.